'Negative' Trial Shows OS Benefit in mCRPC

(MedPage Today) -- Post-radiotherapy ipilimumab (Yervoy) led to a small but persistent long-term survival advantage in a placebo-controlled trial of men with metastatic castration-resistant prostate cancer (mCRPC).
The trial failed to meet the...